Cook Medical has announced the sale of its remaining Otolaryngology, Head & Neck Surgery (OHNS) product lines, excluding employees, facilities and manufacturing equipment, to C2Dx, a portfolio company of Shore Capital Partners.
The transaction is another example of Cook’s commitment to the strategy outlined in its 5-year vision.
The OHNS family of products is C2Dx’s fourth product line acquisition, joining its previous acquisitions of the Shaw Scalpel (from Hemostatix), STIC Intra-Compartmental Pressure Monitor (from Stryker), and T/Pump Localized Temperature Therapy System (from Stryker).
OHNS is an excellent fit for building a leading platform serving the ENT and soft tissue markets and these products extend C2Dx’s domestic and international sales reach and increase the depth of its product portfolio,” said Don Pierce, Partner at Shore and Chairman of the Board of C2Dx.
As part of a comprehensive product review to align with Cook’s strategic vision, we determined that the OHNS product lines would be better served by an organization looking to grow in this space. We’re pleased that C2Dx plans to invest in and grow this portfolio,” said D.J. Sirota, SVP of Cook Medical’s MedSurg division.